Hcverso3: an open-label, phase iib study of faldaprevir and deleobuvir with ribavirin in hepatitis c virus genotype-1b-infected patients with cirrhosis and moderate hepatic impairment

HIGHLIGHTS

• who: Christoph Sarrazin and colleagues from the JWGoethe-University, Frankfurt am Main, Germany, Hannover Medical School, Hannover have published the research work: HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment, in the Journal: PLOS ONE | DOI:10.1371/journal.pone [0168544]. December 28, 2016 of 24/04/2013
• what: This study evaluated the interferon-free oral combination of deleobuvir (non-nucleoside HCV NS5-RNA-polymerase inhibitor) and faldaprevir (HCV NS3/4A-protease inhibitor) with ribavirin in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.